Search Nerddpedia

Lymphoma

** Lymphoma is a group of malignant cancers that arise from lymphocytes, the white‑blood cells that orchestrate the body’s immune response. **CONTENT:** ## Overview Lymphoma encompasses a heterogeneous collection of **blood and lymphatic system tumors** that originate from **B‑cells or T‑cells**, the two main types of lymphocytes. Although the term “lymphoma” can technically describe any abnormal growth of lymphoid tissue, in clinical practice it is reserved for the **cancerous** forms that spread through the lymphatic network, blood, and sometimes other organs. The disease is broadly divided into **Hodgkin lymphoma (HL)**, characterized by the presence of Reed‑Sternberg cells, and **non‑Hodgkin lymphoma (NHL)**, a diverse group that accounts for roughly 85 % of all cases. Patients often present with **painless, enlarged lymph nodes**, most commonly in the neck, armpits, or groin. Systemic “B‑symptoms”—fever, drenching night sweats, and unintended weight loss—signal a more aggressive disease course. Additional complaints may include **pruritus (itching)**, persistent fatigue, and, in advanced stages, organ‑specific symptoms such as abdominal pain from splenomegaly or shortness of breath from mediastinal masses. Because early signs can mimic benign infections, a high index of suspicion and prompt diagnostic work‑up are essential. ## History/Background The first documented description of a lymphoma‑like disease dates to **1845**, when Thomas Hodgkin reported a case of “a disease of the lymphatic system” in a young man with enlarged cervical nodes. The eponymous **Hodgkin lymphoma** was formally named after him in the early 20th century. In the 1950s, the **Rappaport classification** introduced a histologic framework that distinguished between Hodgkin and non‑Hodgkin types, paving the way for modern taxonomy. The **1970s and 1980s** saw the advent of combination chemotherapy (e.g., CHOP) and the first **monoclonal antibody therapy** (rituximab) for B‑cell NHL, dramatically improving survival. Ongoing research into **genomic profiling** and **immune checkpoint inhibition** continues to refine treatment paradigms. ## Key Information - **Epidemiology:** Approximately 9 % of all cancers worldwide are lymphomas, with an incidence of ~5 per 100,000 persons annually in high‑income nations. HL shows a bimodal age distribution (young adults and >55 years), whereas NHL incidence rises steadily with age. - **Risk Factors:** Immunosuppression (HIV, organ transplantation), chronic infections (EBV, H. pylori, HTLV‑1), certain autoimmune diseases, and exposure to chemicals (pesticides, benzene) increase risk. - **Diagnosis:** Core components include **excisional lymph node biopsy**, immunophenotyping (flow cytometry), cytogenetic studies, and imaging (PET‑CT). Staging follows the **Ann Ann Arbor system**, incorporating the number of involved sites and presence of B‑symptoms. - **Treatment:** Therapeutic strategies are tailored to subtype, stage, and patient factors. First‑line regimens range from **ABVD** for early‑stage HL to **R‑CHOP** for many B‑cell NHLs. Advanced or refractory disease may require **high‑dose chemotherapy with autologous stem‑cell rescue**, **CAR‑T cell therapy**, or **immune checkpoint inhibitors** (e.g., pembrolizumab). - **Prognosis:** Five‑year survival exceeds 85 % for early‑stage HL but varies widely for NHL (from >90 % for indolent follicular lymphoma to <30 % for aggressive peripheral T‑cell lymphomas). **When to seek professional care:** Any persistent, painless swelling of lymph nodes lasting more than two weeks, unexplained fever, night sweats, weight loss, or ongoing fatigue warrants evaluation by a healthcare professional. Early diagnosis improves treatment options and outcomes. ## Significance Lymphoma’s impact extends beyond individual patients; it drives advances in **cancer biology, immunology, and targeted therapy**. The success of **rituximab**, the first monoclonal antibody approved for cancer, sparked a wave of biologic agents now standard across oncology. Moreover, lymphoma research has illuminated mechanisms of **immune evasion**, informing the development of **checkpoint inhibitors** that benefit a broad spectrum of malignancies. From a public‑health perspective, survivorship programs address long‑term effects such as secondary malignancies, cardiovascular disease, and psychosocial challenges, underscoring the need for comprehensive, multidisciplinary care. **INFOBOX:** - Name: Lymphoma (Hodgkin and Non‑Hodgkin) - Type: Malignant neoplasm of lymphoid tissue - Date: First described 1845 (Hodgkin’s disease) - Location: Primarily lymph nodes; may involve spleen, bone marrow, extranodal sites - Known For: Pioneering use of monoclonal antibodies and CAR‑T cell therapy in cancer treatment **TAGS:** lymphoma, Hodgkin lymphoma, non‑Hodgkin lymphoma, oncology, immunotherapy, chemotherapy, hematology, cancer research